Key points are not available for this paper at this time.
Design
Review
No takes yet. Share an insight, caveat, or question.
Supports ongoing caution with classic agents; leaves open targeted pathway drug development as a research priority.
Darbar et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: